{"id":281,"date":"2014-06-16T15:12:30","date_gmt":"2014-06-16T13:12:30","guid":{"rendered":"https:\/\/dextechmedical.com\/?page_id=281"},"modified":"2023-02-15T14:38:22","modified_gmt":"2023-02-15T13:38:22","slug":"share-capital","status":"publish","type":"page","link":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/","title":{"rendered":"Share capital"},"content":{"rendered":"

There is only one share class. Each share gives equal rights to the company’s assets and profits and entitlement to a single vote at the Annual General Meeting.<\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Year<\/td>\nEvent<\/td>\nQuata value<\/td>\nIncrease in number of shares<\/td>\nIncrease in share capital<\/td>\nTotal number of shares<\/td>\nTotal share capital<\/td>\nPaid up, including premium<\/td>\nCompany value, premoney<\/td>\n<\/tr>\n
2004<\/td>\nFormation<\/td>\n100<\/td>\n1 000<\/td>\n100 000<\/td>\n1 000<\/td>\n100 000<\/td>\n100 000<\/td>\n0<\/td>\n<\/tr>\n
2006<\/td>\nNew share issue<\/td>\n100<\/td>\n1 100<\/td>\n110 000<\/td>\n2 100<\/td>\n210 000<\/td>\n860 000<\/td>\n781 818<\/td>\n<\/tr>\n
2006<\/td>\nNew share issue<\/td>\n100<\/td>\n234<\/td>\n23 400<\/td>\n2 334<\/td>\n233 400<\/td>\n750 000<\/td>\n6 730 769<\/td>\n<\/tr>\n
2007<\/td>\nNew share issue<\/td>\n100<\/td>\n123<\/td>\n12 300<\/td>\n2 457<\/td>\n245 700<\/td>\n2 500 000<\/td>\n47 439 024<\/td>\n<\/tr>\n
2010<\/td>\nShae split (100:1)<\/td>\n1<\/td>\n243 243<\/td>\n–<\/td>\n245 700<\/td>\n245 700<\/td>\n–<\/td>\n–<\/td>\n<\/tr>\n
2010<\/td>\nNew share issue<\/td>\n1<\/td>\n6 143<\/td>\n6 143<\/td>\n251 843<\/td>\n251 843<\/td>\n2 500 201<\/td>\n99 999 900<\/td>\n<\/tr>\n
2011<\/td>\nNew share issue<\/td>\n1<\/td>\n25 185<\/td>\n25 185<\/td>\n277 028<\/td>\n277 028<\/td>\n8 499 939<\/td>\n84 997 027<\/td>\n<\/tr>\n
2013<\/td>\nNew share issue<\/td>\n1<\/td>\n5 540<\/td>\n5 540<\/td>\n282 568<\/td>\n282 568<\/td>\n1 994 400<\/td>\n99 730 080<\/td>\n<\/tr>\n
2014<\/td>\nFondemission<\/td>\n1,8<\/td>\n–<\/td>\n226 054<\/td>\n282 568<\/td>\n508 622<\/td>\n–<\/td>\n–<\/td>\n<\/tr>\n
2014<\/td>\nShare split 40:1<\/td>\n0,045<\/td>\n11 020 152<\/td>\n–<\/td>\n11 302 720<\/td>\n508 622<\/td>\n–<\/td>\n–<\/td>\n<\/tr>\n
2014<\/td>\nNew share issue<\/td>\n0,045<\/td>\n2 860 000<\/td>\n128 700<\/td>\n14 162 720<\/td>\n637 322<\/td>\n30 030 000<\/td>\n118 678 560<\/td>\n<\/tr>\n
2016<\/td>\nNew share issue<\/td>\n0,045<\/td>\n590 113<\/td>\n26 555<\/td>\n14 752 833<\/td>\n663 877<\/td>\n15 342 938<\/td>\n368 230 720<\/td>\n<\/tr>\n
2019<\/td>\nNew share issue<\/td>\n0,045<\/td>\n167 645<\/td>\n7 544<\/td>\n14 920 478<\/td>\n671 422<\/td>\n10 058 700<\/td>\n885 169 980<\/td>\n<\/tr>\n
2021<\/td>\nNew share issue<\/td>\n0,045<\/td>\n3 565 379<\/td>\n160 442<\/td>\n18 485 857<\/td>\n831 864<\/td>\n46 349 927<\/td>\n193 966 214<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

There is only one share class. Each share gives equal rights to the company’s assets and profits and entitlement to a single vote at the Annual General Meeting.   Year […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":277,"menu_order":20,"comment_status":"closed","ping_status":"closed","template":"page-wide.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-281","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nShare capital | DexTech<\/title>\n<meta name=\"description\" content=\"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Share capital | DexTech\" \/>\n<meta property=\"og:description\" content=\"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-15T13:38:22+00:00\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/\",\"url\":\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/\",\"name\":\"Share capital | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2014-06-16T13:12:30+00:00\",\"dateModified\":\"2023-02-15T13:38:22+00:00\",\"description\":\"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors\",\"item\":\"https:\/\/dextechmedical.com\/en\/investors\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Share capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Share capital | DexTech","description":"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/","og_locale":"en_US","og_type":"article","og_title":"Share capital | DexTech","og_description":"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General","og_url":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/","og_site_name":"DexTech","article_modified_time":"2023-02-15T13:38:22+00:00","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/","url":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/","name":"Share capital | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2014-06-16T13:12:30+00:00","dateModified":"2023-02-15T13:38:22+00:00","description":"There is only one share class. Each share gives equal rights to the company's assets and profits and entitlement to a single vote at the Annual General","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/en\/investors\/share-capital\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/en\/investors\/share-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Investors","item":"https:\/\/dextechmedical.com\/en\/investors\/"},{"@type":"ListItem","position":3,"name":"Share capital"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/pages\/281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=281"}],"version-history":[{"count":7,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/pages\/281\/revisions"}],"predecessor-version":[{"id":1689,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/pages\/281\/revisions\/1689"}],"up":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/pages\/277"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}